



FOR IMMEDIATE RELEASE

15 FEBRUARY 2006

ANGEL BIOTECHNOLOGY HOLDINGS PLC
(“Angel” or “the Company”)

Angel announces extension to contract with Chr. Hansen A/S

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, that was recently admitted to trading on AIM, and Chr. Hansen A/S, a company providing innovative ingredient solutions for the food, pharmaceutical, nutritional and agricultural industries, are pleased to announce an extension to the contract signed in 2005. Terms of the contract have not been disclosed.

Under the contract, Angel will continue to develop improved processes for the manufacturing of a currently marketed fermented product. The project, which uses Angel’s state of the art high throughput screening technology, has already met the objectives of improving the productivity of the manufacturing process, thereby reducing the overall capital expenditure necessary to produce each unit of product. The additional work will seek further improvements to the process.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: “We are very pleased to be continuing work with Chr. Hansen. Chr. Hansen’s strategy of sourcing high technology solutions to strengthen its competitive position around its products matches well with Angel’s ability to provide such industrial innovative solutions. We welcome the continuation of this project, which has already met its original objectives, as it gives the opportunity to provide further improvements to the client’s process.”

Eric Johansen, Vice President, Molecular Microbiology of Chr. Hansen A/S, said: “Continuing our collaboration with Angel Biotechnology will enable us to incorporate the latest research findings thereby increasing our benefits from this fruitful interaction. We have benefited greatly from working with Angel Biotechnology using the competences and equipment they already have in place. This allows us to continue improving our processes without investing valuable R&D time in first developing the relevant competences and investing in the required equipment.”

For further information, please call:

Angel Biotechnology Holdings plc
Gordon Sherriff – COO

Tel 01670 591920
Tel 07951 057016

Buchanan Communications
Lisa Baderon/Mary-Jane Johnson

Tel 020 7466 5000

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and was admitted to trading on AIM in November 2005.

About Chr. Hansen A/S

Chr. Hansen develops innovative ingredient solutions for the food, pharmaceutical, nutritional and agricultural industries in close cooperation with its customers and partners.

The company's focus is to be a specialist in select industries and thereby provide the best ingredients for the industries we operate in. This gives our customers an essential competitive advantage. More about Chr Hansen: www.chr-hansen.com